ALKERMES
SpecialtyALKERMES is a specialty pharmaceutical company focused on Respiratory, Gastroenterology. Key products include LYBALVI.
ALKERMES at a Glance
- Fast trial execution (13 months median completion)
ALKERMES's Key Drugs
ALKERMES's core commercial portfolio centers on LYBALVI, LUMRYZ, ARISTADA, spanning Respiratory and Gastroenterology — its most strategically important drugs approved in the last 15 years.
ALKERMES's Recent FDA Approvals
New NDA/BLA approvals for ALKERMES over the last two years — novel drugs only, excluding generics and label supplements.
ALKERMES's Therapeutic Areas
ALKERMES's approved drugs and pipeline span 2 therapeutic areas, led by Respiratory and Gastroenterology, across 0 biologic and 5 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ALKERMES's Top Competitors
ALKERMES's closest competitors by therapeutic-area and drug-target overlap include MALLINCKRODT, LEGACY, and COREPHARMA. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ALKERMES Pipeline Snapshot
ALKERMES has 2 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 1 Phase 1.
Phase 3 Readout Calendar Pro
6 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LYBALVI leads revenue
- • 4 key drugs tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 20/27 completed
- • Speed: 13 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (4)
Discontinued (0)
Company Info
- First Approval
- 2006-04-13
- Latest
- 2026-01-30
- Applications
- 5
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges